Introduction: Immune and inflammatory responses developed by the patients with Coronavirus Disease 2019 (COVID-19) during rapid disease progression result in an altered level of biomarkers. Therefore, this study aimed to analyze levels of blood-based biomarkers that are significantly altered in patients with COVID–19.

Methods: A cross-sectional study was conducted among COVID-19 diagnosed patients admitted to the tertiary care hospital. Several biomarkers – biochemical, hematological, inflammatory, cardiac, and coagulatory – were analyzed and subsequently tested for statistical significance at P<0.01 by using SPSS version 17.0.

Results: A total of 1,780 samples were analyzed from 1,232 COVID-19 patients (median age 45 years [IQR 33-57]; 788 [63.96%] male). The COVID-19 patients had significantly (99% CI, p<0.001) elevated glucose, urea (p=0.001), alanine transaminase (ALT), aspartate aminotransaminase (AST), alkaline phosphatase (ALP), lactate dehydrogenase (LDH) levels, total white blood cell count (WBC), C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), ferritin, D-Dimer, and creatinine phosphokinase-MB (CPK-MB, p=0.004) as compared to control group. However, the levels of total protein, albumin, and platelets were significantly lowered in COVID-19 patients as compared to control group. The elevated levels of glucose, urea, direct bilirubin, WBC, CRP, prothrombin time (PT), D-Dimer, and LDH were significantly associated with in-hospital mortality among COVID-19 patients.

Conclusions: Assessing and monitoring the elevated levels of glucose, urea, ALT, AST, ALP, ferritin, DB, WBC, CRP, PCT, LDH, D-Dimer, PT, and CPK-MB and the lowered levels of total protein, albumin, and platelet could provide a basis for evaluation of improved prognosis and effective treatment in patients with COVID-19.